Literature DB >> 15907040

Injury caused by self-inoculation with a vaccine of a Freund's complete adjuvant nature (Gudair) used for control of ovine paratuberculosis.

P A Windsor1, R Bush, I Links, J Eppleston.   

Abstract

OBJECTIVE: To document the occurrence and consequences of accidental self-inoculation of vaccinators (producers, farm employees, contractors) with the recently registered Gudair vaccine for the control of ovine paratuberculosis in Australia. DESIGN AND PROCEDURE: A survey of the first 50 primary producers permitted to use the vaccine in sheep and a description of six cases of accidental self-inoculation for which medical attention was sought, and which occurred after the vaccine became widely available.
RESULTS: The survey recorded that, of 37 respondents vaccinating 155,523 sheep, there were 21 incidents of exposure to the vaccine, an overall rate of one incident per 7406 vaccinations. In five of these incidents there was only superficial skin contact with vaccine; in 16 there was needle penetration without vaccine injection. There were no reports of self-inoculation with vaccine. Six cases of self-inoculation with Gudair vaccine that required medical intervention are described. Of these five were in males and one in a female; four involved injection of vaccine into the leg and single cases involved a foot or hand. Most cases required surgical removal of the injected vaccine to allow wound repair; three required extensive surgery and open drainage. Even with surgery recovery took as long as 9 months. Possible risk factors for self-inoculation and the resulting outcome are discussed.
CONCLUSIONS: Gudair ovine paratuberculosis vaccine can cause prolonged granulomatous inflammation if inadvertently injected into human tissue. After.self-inoculation, early surgical debridement of the damaged tissue and drainage to remove the vaccine material are advised to avoid progression to extensive necrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15907040     DOI: 10.1111/j.1751-0813.2005.tb11654.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  7 in total

1.  Assessment of live candidate vaccines for paratuberculosis in animal models and macrophages.

Authors:  Gabriella M Scandurra; Geoffrey W de Lisle; Sonia M Cavaignac; May Young; R Pamela Kawakami; Desmond M Collins
Journal:  Infect Immun       Date:  2009-12-28       Impact factor: 3.441

2.  Evaluation of a Salmonella vectored vaccine expressing Mycobacterium avium subsp. paratuberculosis antigens against challenge in a goat model.

Authors:  Syed M Faisal; Falong Yan; Tsai-Tzu Chen; Nicodemus M Useh; Shanguang Guo; Weiwei Yan; Shih-Jon Wang; Amy L Glaser; Sean P McDonough; Bhupinder Singh; Yung-Fu Chang
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

3.  Case definition terminology for paratuberculosis (Johne's disease).

Authors:  R J Whittington; D J Begg; K de Silva; A C Purdie; N K Dhand; K M Plain
Journal:  BMC Vet Res       Date:  2017-11-09       Impact factor: 2.741

4.  The immunogenicity and tissue reactivity of Mycobacterium avium subsp paratuberculosis inactivated whole cell vaccine is dependent on the adjuvant used.

Authors:  D J Begg; O Dhungyel; A Naddi; N K Dhand; K M Plain; K de Silva; A C Purdie; R J Whittington
Journal:  Heliyon       Date:  2019-06-18

5.  Exposure rate of needlestick and sharps injuries among Australian veterinarians.

Authors:  Peter A Leggat; Derek R Smith; Richard Speare
Journal:  J Occup Med Toxicol       Date:  2009-08-28       Impact factor: 2.646

6.  Cellular and humoral immune responses in sheep vaccinated with candidate antigens MAP2698c and MAP3567 from Mycobacterium avium subspecies paratuberculosis.

Authors:  Ratna B Gurung; Auriol C Purdie; Richard J Whittington; Douglas J Begg
Journal:  Front Cell Infect Microbiol       Date:  2014-07-16       Impact factor: 5.293

Review 7.  Ovine Paratuberculosis Control in Australia Revisited.

Authors:  Peter Windsor; Richard Whittington
Journal:  Animals (Basel)       Date:  2020-09-10       Impact factor: 2.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.